LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

44.89 0.83

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.5

Max

44.99

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.61% upside

Turustatistika
By TradingEconomics
Turukapital	132M 3.4B
Eelmine avamishind	44.06
Eelmine sulgemishind	44.89

Uudiste sentiment

By Acuity

50%

184 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. dets 2025, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Buys AI-Device Maker Limitless

5. dets 2025, 19:39 UTC

Suurimad hinnamuutused turgudel

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5. dets 2025, 19:17 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5. dets 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

5. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5. dets 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5. dets 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5. dets 2025, 21:03 UTC

Market Talk

Tulu

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5. dets 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5. dets 2025, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5. dets 2025, 20:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5. dets 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. dets 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5. dets 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5. dets 2025, 19:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5. dets 2025, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:24 UTC

Omandamised, ülevõtmised, äriostud

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5. dets 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5. dets 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5. dets 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5. dets 2025, 17:44 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

5. dets 2025, 17:44 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Correction to Imax Market Talk

5. dets 2025, 17:35 UTC

Market Talk

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5. dets 2025, 17:25 UTC

Market Talk

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

24.61% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 24.61%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

184 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.